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ABSTRACT 
   Background: Tuberculosis remains a major challenge to public health worldwide. According 
WHO, the prevalence of tuberculosis in prisons is very high, accounting for up to 25% of the TB 
burden in a given country, and is reported to be 10-to 100-folds higher than in the general 
population. Prisons are increasingly becoming ideal breeding grounds for the concentration and 
dissemination of TB including MDR-TB TB, from which infection is transmitted to the general 
population. 
Objective: The aim of this study was to determine the prevalence of pulmonary tuberculosis and 
MDR-TB in prison settings of North Gondar zone (NGZ). 
Materials and Methods: A cross-sectional study was conducted from February to April, 2015 
among prisoners of NGZ. All prison inmates who had history of cough for ≥ 2 weeks were 
included in the study. Socio-demographic variables and potential risk factors were assessed using 
structured questionnaire. Pre and post HIV test counseling was provided after written consent 
obtained from PTB suspected inmates. Three sputum samples were collected and kept in ice box 
and transported to the University of Gondar. Sputum samples were examined through LED-FM 
and positive samples were further examined using Gene Xpert MTB/RIF assay for MDR-TB. 
Data was analyzed using SPSS version 20 and P-value < 0.05 was taken as significant. 
Results: A total of 282 prison inmates suspected for PTB were enrolled in the study. The overall 
prevalence of smear-positive PTB was 5.3% (15/282). All smear positive PTB cases were found 
non-MDR-TB cases. The magnitude of TB/HIV co-infection among PTB cases was found 24%. 
Smear positive PTB infection was significantly associated with smoking (AOR =7.16, 95% CI= 
1.76-29), malnourished (BMI <18.5kg/m2) (AOR =16.26, 95% CI= 4.5-67.9) and number of 
inmates per cell >100 (AOR= 10.32= 95% CI=3.29-8.51). 
Conclusion and Recommendation: In this study, the prevalence of PTB among prisoners was 
found to be 2 times higher than in the general population. No MDR-TB case was detected. 
Factors such as TB/HIV co-infection, malnourished, overcrowding, smoking, previous history of 
contact with TB patient were associated with PTB infection. Special attention should be given to 
reduce spread of TB in prisons. 
Keywords: Prison, MDR-TB, Pulmonary tuberculosis
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1. INTRODUCTION 
1.1 Background 
Tuberculosis (TB) is an air borne infectious disease caused by the bacillus Mycobacterium 
tuberculosis. It typically affects the lungs (pulmonary TB) it can affect also other sites as well 
(extra pulmonary TB). The disease spreads in the air when people who are sick with pulmonary 
tuberculosis (PTB) expel bacteria, for example by talking, coughing, singing, sneezing and 
spiting. Overall, a relatively small proportion of individuals infected with Mycobacterium 
tuberculosis can develop TB disease; nevertheless, the probability of developing the disease is 
much higher among people infected with human imuno-deficiency virus (HIV) [1].  
Once a person develops the disease, PTB, there will be several suggestive clinical presentations, 
especially two weeks‟ or more duration of cough, production of sputum and weight loss are 
important for the diagnosis of PTB. Others respiratory symptoms like chest pain, haemoptysis, 
breathlessness and/or constitutional symptoms like night sweats, fever, loss of appetite, fatigue, 
can also occur [2]. 
Multidrug resistant TB (MDR-TB), defined as resistance to at least isoniazid (INH) and 
rifampicin (RIF), are of the two most important first-line anti-TB drugs, has been spreading 
rapidly in recent years. Development of drug resistance TB is mainly associated with ineffective 
TB control programmes due to inadequate therapy, interrupted drug supply, poor patient 
compliance, and inappropriate treatment regimens [3]. 
‘Prison‟ is a term used for any place of detention. It includes centers for pre-trial and convicted 
prisoners as well as centers for juvenile offenders and illegal immigrants. On any day, it is 
estimated that the world‟s prisons hold 8-10 million prisoners. However 4-6 times this number 
passes through prisons each year, because of the high turnover of the population. Prisons act as a 
reservoir for TB, pumping the disease into the civilian community through staff, visitors and 
inadequately treated former inmates [4]. 
Failure to effectively treat the patient will lead to further amplification of drug resistance leading 
to the development of MDR-TB [5]. Patients with MDR-TB on treatment should be nursed in 
isolation until sputum smear microscopy and cultures turn negative. Close monitoring of the 
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patient with Direct Observed Treatment, Short-course (DOTS) and follow-up is required after 
patient is discharged from the treatment facility. The best method of infection control remains 
the early diagnosis of infectious cases and the prompt initiation of effective treatment to prevent 
the emergence of drug-resistant TB [6]. 
1.2 Statement of the problem 
Tuberculosis in the prison setting poses a major public health problem worldwide. Globally 
around 8.6 million new TB cases in 2012 were reported and 1.3 million die every year as a result 
of TB [7]. Prisons are settings in which TB transmission occurs and high rates of active TB have 
been reported worldwide, especially in countries of the former Soviet Union [8] and in Sub-
Saharan Africa (SSA) [9], where TB in prisons threatens not only prison inmates, but also prison 
staffs who eventually interact directly with their families and community when they leave work 
[10]. This indicates that TB in prison is not only the concern of prisoners, but concerns the wider 
society at large and MDR-TB has become a major public health problem and presents new 
barriers to the control of TB in the world [11]. Nearly half a million cases of MDR-TB emerge 
every year, but only 3% of them get treatment globally and 110,000 die annually [12].TB and 
HIV co- infection and the exponential increase in MDR-TB are greatly responsible for the 
resurgence of tuberculosis [2].  
According to the World Health Organization (WHO) 2013, the prevalence of TB in prisons is 
very high, accounting for up to 25% of the TB burden in a given country, and estimated to be 10-
to 100-folds higher than the general population [13].  
High levels of MDR-TB have been reported from some prisons with up to 24% of TB cases 
suffering from MDR-TB cases of the disease [14]. Prisons are increasingly becoming ideal 
breeding grounds for the concentration and dissemination of TB including MDR-TB, from which 
infection is transmitted to the general population [15]. In some studies there is high prevalence 
TB in prisons. For instance, study reports documented a 500 TB cases per 100.000 inmates in 
New York City jails, and 4,960 cases per100, 000 inhabitants in southern of Brazil prisons [16, 
17]. 
 In Africa, the prevalence of tuberculosis infection in prisons was previously reported higher, 
although the magnitude is different from country to country. Accordingly, a prevalence of 3, 574 
per 100,000, 8937 TB cases per 100,000 and 6821 cases per 100,000 respectively were reported 
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in Malawi, in Zambia and Madagascar, respectively [18,19,20]. Demonstrating a 10 to 35 times 
higher prevalence of TB in prisons than in the general population. 
Ethiopia ranks the 7
th
 among the world‟s 22 high TB burden countries. According to WHO, 2013 
report, the prevalence, incidence, and mortality rates in the country were 224 per100, 000, 247 
per100, 000, and 18 per100, 000 populations, respectively. The same report showed that 1.6% of 
new TB patients and 12% of previously treated patients had MDR-TB [21]. Nevertheless, efforts 
had been made to treat TB cases in prisons and to control tuberculosis infection in some African 
countries. For example, Malawi has published guidelines on the implementation of specific 
interventions for TB in prisons [22]. The magnitude of tuberculosis infection among inmates of 
prisons in Ethiopia is not fully determined. However, there are very few study reports that 
estimated the prevalence of smear positive pulmonary tuberculosis infection in prisons. For 
example, a prevalence of 1913 per 100,000 inmates was reported by the year 2008 in Eastern 
Ethiopia [23] and another study in the Southern part of Ethiopia documented a 629/100,000 
prevalence of smear positive pulmonary tuberculosis infection among prisoners by the year 2011 
[24].  
 Previous report from a single prison in Gondar town prison demonstrated a prevalence of 1482 
per 100,000 smear positive pulmonary tuberculosis infections among prison inmates [25]. 
Because this report was made from single prison in Gondar town prison, we believe that the 
report lacks representativeness as there are prisons in different weredas of North Gondar zone 
other than the Gondar prison present in Gondar town.  Moreover, the previous study report also 
lacks the MDR-TB pattern of tuberculosis infection in the aforementioned prison. Thus, this 
study aimed to determine the prevalence of pulmonary TB and MDR-TB infection among the 
prisons of North Gondar zone.  
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2. LITERATURE REVIEW 
Despite the fact that the global focus on TB control is on early diagnosis and treatment of people 
in high TB and TB/HIV-endemic countries, people in prisons are often neglected reservoirs for 
TB transmission threatening those in the outside community [2].  
A study conducted in Thailand in the year 2007 shows that the prevalence of PTB was 1.2% or a 
point prevalence of 354.8/100 000 in prison inmates [26]. Across sectional study conducted in 
southern Brazilian prison showed a 3.8% tuberculosis prevalence (72/1,900 inhabitants). Of the 
TB cases, 17 patients (23.6%) had at least one prior TB episode and were considered retreatment 
cases. Thus, the incidence of new cases was 2.9% (55/1,900 inhabitants). The study also reported 
that 8 prisoners (11%) had a previous contact with TB outside the institution and also after 
imprisonment [17]. 
A study conducted in Dhaka central jail, Bangladesh reported that, among 1,781 TB suspects 245 
(13.8%) was positive for PTB. Moreover, resistance to Isoniazid (INH), Rifampicin (RIF), was 
11.4%, and 0.8%, respectively [27]. There are also reports that documented MDR-TB infection 
among prisoners in different parts of the world. For example, a cross sectional survey conducted 
in Russia by the year 2001–2002 showed prevalence of INH and RIF resistance among new 
prison TB cases was 38.0% and 25.2% , respectively [28]. In Uzbekistan the prevalence of 
MDR-TB infection was reported 23.2% among new TB cases and 62% among retreatment 
prisoners [29].  
There are also reports which show high prevalence of PTB in Africa, in Cameron; Noeske et al 
reported a 3.5% point prevalence of pulmonary tuberculosis infection among prisoners. They 
also documented a 25% sero-prevalence of HIV infection among prisoners co-infected with 
tuberculosis but the prevalence of HIV was found by far lower (10.4%) among inmates that had 
no clinical signs for pulmonary tuberculosis infection [30]. 
A cross sectional study carried out at Mbarara central prison, Uganda between June 2012 to 
August 2012 showed a total of 648 in mates were screened and 248 inmates enrolled in the 
study, of  which 2%(5/248) of them were positive for PTB [31].Another study conducted in 
Botswana jailed prisons shows that, from those of 1,027 prisoners and 263 guards at 4 prison 
settings during April-May 2002.The point prevalence of TB disease among prisoners was 
3,797/100,000 and among guards it was 2,662/100,000.Of those 2 prisoners had resistance to 
5 
 
INH; 1 guard was resistant to INH, ETB and ST [32]. A study conducted from 2000-2001 in 
Zambian prisons found a 23.8% (n=40) resistance to at least one anti-tuberculosis drugs; where 
9.5% (n=16) of them were MDR-TB or point prevalence of 262 per 100,000 populations, this 
rate was found to be on the upper limit of resistance rates reported among African countries [19]. 
But a study conducted in this setting in 2011shows, of the 160 individuals found be positive for 
tuberculosis, 1 (0.6%) had MDR-TB and 4 (2.5%) had tuberculosis that was resistant to INH 
only which decreases slightly this may be due published guidelines on the implementation of 
specific interventions for MDR-TB in prisons [33]. 
Prison tuberculosis infection was also previously reported in different parts of Ethiopia. Recently 
Abebe et al, (2008)  conducted a survey in three major prisons in the Eastern parts of Ethiopia 
and found that among 371 pulmonary tuberculosis suspected prison inmates, 33 (8.9%) were 
confirmed as PTB positive . The study also reported that the point prevalence of PTB among 
prisoners in the area was 1913 per100 000, about seven times higher than that of the general 
population [23]. Another study conducted by Zerdo et al, (2012) in the Southern parts of 
Ethiopia aimed to determine the prevalence of pulmonary tuberculosis infection among prison 
inmates who had cough for at least two weeks found to be a prevalence of 19.4% (24/124) [24]. 
The recent report of Moges et al, (2011) in Gondar town prison showed a prevalence 10.4% 
smear positive PTB infection among tuberculosis suspected prisoners. The prevalence of HIV 
infection among the inmates was 7.6% and the prevalence of HIV infection among TB infected 
inmates was 34.6% (9/26) [25]. 
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2.1 Risk factors for prison tuberculosis infection 
Generally, persons at high risk for developing TB disease fall into two categories: persons who 
have been recently infected with TB bacteria and persons with medical conditions that weaken 
the immune system. Acquisition of tuberculosis bacteria could be due to close contacts of a 
person with infectious TB disease and groups of people with higher risk for TB transmission 
includes prisoners and persons with HIV infection [34]. 
Prisoners constitute a high risk group for acquisition of Mycobacterium tuberculosis infection 
and development of MDR-TB compared with the general population due to the overcrowding, 
high number of inmates per cell, poor ventilation, generally low socioeconomic status, poor 
nutrition, and poor health condition of prison inmates which can predispose imprisoned people 
to a high risk of TB incidence [35]. Prison inmates are often highly mobile, circulating within 
the prison from cell to cell and from prison to prison for another incarceration, and they may be 
released after some time. The incarcerated time, age, number of prisoners per cell, previous 
history of intravenous drug use, history of alcohol consumption, cigarette smoking and HIV 
infection are among the possible risk factors that may contribute for tuberculosis transmission 
in prisons [36].  
Studies also have shown that malnutrition and/or a BMI<18·5 kg/m2 were associated with 
increased risk of developing TB in prisons. For instance, a study in Zambia found that nutritional 
status and food intake was universally poor in all surveyed prisons [33]. Similarly, studies in the 
Ethiopia, Russia, Cameroon, Tanzania and Ivory Coast reported a BMI < 18·5 kg/m2 as a 
significant predictor of TB [25, 27, 30, 37 and 38]. 
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3. SIGNIFICANCE OF THE STUDY  
 
Understanding the epidemiology of tuberculosis in prisons is necessary for governmental and 
other agencies to contribute in the implementation of effective tuberculosis control programs in 
prisons. The high prevalence of tuberculosis infection in the general society of the country in 
general and Gondar in particular could have contributed to the burden of TB in prisons in North 
Gondar administrative zone. In Ethiopia, there are limited studies regarding the prevalence of TB 
in prisons. However, previous report from Gondar showed a significantly higher prevalence of 
tuberculosis in a single prison. Nevertheless, the study report had not showed the drug 
susceptibility pattern of Mycobacterium tuberculosis isolates from that prison.  We believe that 
understanding the magnitude of MDR-TB could contribute for effective treatment, prevention 
and control of tuberculosis infection in prisons in particular and the general community in 
general. Moreover, MDR-TB emphasizes the urgent need for the effective control of TB in 
prisons because it represents a health problem both in the penitentiary system and the community 
into which inmates are released. Thus, this study assessed the prevalence of PTB and MDR-TB 
with associated risk factors in prisons of north Gondar. Results of this study will contribute in 
designing strategies for prevention and control of TB prevalence and MDR-TB; strengthening 
the information available so far and encourage policy makers to design effective strategies to 
combat TB prevalence and MDR-TB in the study area and will serve as base line data to conduct 
further studies. 
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4. OBJECTIVES 
    4.1 General objective  
 The overall aim of this study was to determine the prevalence and multi drug resistance patterns 
of pulmonary tuberculosis in prison settings of North Gondar zone, North West Ethiopia. 
   4.2 Specific objectives  
- To determine the magnitude of pulmonary tuberculosis in four prisons of North Gondar 
administrative zone 
- To assess the burden of MDR-TB infection in these prisons  
- To identify the factors that may contribute for the accusation of tuberculosis in these prisons. 
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5. MATERIALS AND METHODS 
5.1 Study Design  
A cross-sectional study was conducted among four prisons found in North Gondar administrative 
zone to estimate the prevalence and multi drug resistance of pulmonary tuberculosis. 
  5.2 Study area and period  
The study was conducted from February - April, 2015 at three prisons (Debark, Dabat, Chilga 
and Gondar town) of North Gondar zone, Northwest Ethiopia. North Gondar zone has 21 
weredas with 539 kebeles, 2 administration towns with 37 kebeles, according to the 2007 
Ethiopian census report, North Gondar zone has a total population of 2,929,628, of 
whom 1,486,040 are men and 1,443,588 women .In this zone, there is one zonal and 21 weredas 
police stations and there are three large prisons that could hold about 1500-3500 prisoners. They 
receive mainly sentenced and some pre-trial prisoners from several surrounding weredas. 
5.3 Population 
  5.3.1 Source population 
The source of the sample was all the four prison inmates present in North Gondar zones.  
 5.3.2 Study population 
 All prison inmates who had cough for more than or equal to two weeks during the study period.  
5.4 Inclusion criteria  
Prisoners who are willing to participate and had two and above weeks duration of cough were 
included in the study. 
5.5 Exclusion criteria 
Prisoners who had two and above weeks duration of cough but were unable to produce sputum 
and inmates who are on anti-TB treatment and/or provided incomplete information were also 
excluded from the study. 
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5.6 Definitions of terms 
A positive AFB smear:  when at least two out of three smear results are positive or one positive 
result in case of HIV positive individuals is taken as smear  
A negative AFB smear: When the result of the three sputum smears are negative for AFB  
Multidrug resistant TB (MDR-TB) - Resistance to at least isoniazid and rifampcin  
5.7 Variables  
     5.7.1 Dependent Variable  
Prevalence of PTB and MDR TB 
    5.7.2 Independent Variables  
 Age, sex,                                               -Smoking cigarette 
 Educational status                                 -Residence before incarceration 
 Marital status                                         -Time occurrence of cough                                            
 Length of staying in prison                    - History of previous contact with active TB      
 Frequency of imprisonment                    -Nutritional status 
 Prisoners per cell                                     -Sharing food and other materials                         
 Pervious of Rt with TB                            -Window opening practice   
 HIV status                                                -Occupation before incarceration 
 Duration of cough                                                
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5.8 Sample size and Sampling technique  
 5.8.1 Sample size  
The minimum sample size was calculated by using single population proportion formula. 
Previous study done in North Gondar zone prison with prevalence of 10.4% was taken for 
sample size determination [25]. Total sample size was calculated as follows: ni= (Za/2)
2
p (1-
p)]/d
2
  
Where   ni= Initial sample size         Z=95% confidence interval 
           d= Margin of error b/n the sample and the population (d=4%) 
          P= 10.4% 
     ni= (1.96)
2
x0.104(1-0.104)         = 223 
                (0.04)
2
 
By reviewing the record the average prison inmates in the three prisons of north Gondar are 
3900,since this source population is less than ten thousand(N<10,000) sample size correction 
was used as follows: 
 
nf =       in            where ; nf= the final sample size; N=source population , nf=  223   
       1+ni/N         
1+223/3900 
Considering a 10% non response rate the final sample size will be 212.8+22.3=235 
But during study all inmates who fulfill the inclusion criteria were enrolled, hence they were 282  
5.8.2 Sampling technique  
At the time of the study about 3900 inmates were held in the four prisons of the north Gondar 
zone. A mass screening strategy was used to identify PTB suspects. This strategy provides an 
equal chance of selecting eligible individuals, and reduces a chance of losing PTB suspects. First 
all prisoners were collectively questioned for the presence of cough then those prisoners with 
cough were individually interviewed about the duration of cough. Prisoners who had cough 
history of two weeks and above were included in the study. In this case, a total of 282 prisoners 
were actively selected to participate in the study. Once the inmate recruited eligible for the study, 
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socio-demographic characteristics, other study variables and sputum samples were collected 
following standard operational procedures. Moreover, all recruited participants were screened for 
HIV infection after getting consent from each inmate. Concerning HIV testing, nurses   
Providing Initiative counseling and Testing (PICT) in the prison clinics were involved. Prisoners 
with positive sputum smears were placed on anti-tuberculosis treatment as recommended by 
National Tuberculosis and Leprosy Control Program (NTLCP) guidelines [39], while smear-
negative patients were given a 10-day course of broad spectrum antibiotic treatment. 
5.9 Data collection and Laboratory methods 
     5.9.1 Socio-demographic data 
  Information on socio-demographic characteristics, imprisonment, number of prisoners per cell, 
history of previous treatment with TB, previous exposure to TB, window opening practice, 
cigarette smoking, and others was collected using a structured and pretested questionnaire.  
    5.9.2 Sample collection and Processing 
Three spot- morning-spot sputum samples were collected from patients having cough of two and 
above weeks duration using coded and clean plastic containers by the investigator. 
 Sputum microscopy using a light emitting diode (LED) fluorescence microscopy  
Spot- morning-spot sputum samples were collected from patients having cough of two and above 
weeks duration. Sputum-smear microscopy using a light emitting diode (LED) fluorescence 
microscopy (FM) was done at the University of Gondar on the day of collection following the 
manufacturer‟s procedures (PARTECGmbH). A smear was prepared from each sputum sample, 
stained and examined microscopically. Sputum was smeared on a labeled and clean frosted slides 
and allows to dry following fixing with heat and flood the slide with 0.1% auraminO for 20‟s and 
decolorized the smear by covering the glass slides with 0.5% acid-alcohol solution then after 
some minutes counter stain the smear by covering the glass slides with 0.1% potassium 
permanganate solution by incubating for one minute, washing with water in each of the above 
steps. The results of the sputum microscopy were graded following the WHO guide lines [40]. 
 The remaining portion of sputum samples was stored at 4 
0
C in refrigerator and smear positive 
samples were transported and done at Gondar University Hospital for Gene Xpert to assess the 
MDR -TB.  
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Gene Xpert MTB/RIF assay 
All positive PTB results using the LED fluorescent microscopy were further examined using the 
Gene Xpert MTB/RIF (Cepheid Gene Xpert system) to detect for rifampicin (RIF) resistance 
following the standard procedure. In brief, sample reagent was added to sample with 2:1 (v/v) 
proportion and   mixed by hand shaking and incubated at room temperature for 15 minutes. After 
the incubation step, using the sterile pipette transfer 2 ml of the treated sample to the cartridge 
and the run is initiated. Then after about 2 hours, results interpreted and displayed by the 
machine as MTBC detected/not-detected and „„RIF resistance not detected or detected”. 
Nutritional assessment 
Body weight was determined to the nearest 0.1 kg using an electronic digital scale and height 
was measured to the nearest 0.1 cm. Body mass index (BMI), defined as the weight in kilogram 
of the individual divided by the square of the height in meter, was used to determine the 
nutritional status of the patients as under nutrition (BMI < 18.5 kg/m2) and normal (BMI = >18.5 
kg/m2) [41]. 
5.9.   Quality Control 
      Data quality was maintained using translated questionnaires from English to Amharic 
language. Pre-testing of the questionnaire was done before data collection for completeness and 
appropriateness. Moreover, quality of reagents was done using known positive and negative 
controls. 
5.10. Data analysis and Interpretation  
Data was checked for completeness, cleaned manually and entered and analyzed using SPSS 
version 20 statistical package. Means and standard deviations were calculated for continuous 
variables while crude and adjusted Odds ratios (OR) with 95 % CI was calculated to check 
statistical association between the dependent and independent variables using the binary logistic 
regression and multivariable logistic regression models.  
All variables of the study were initially tested for association with smear positivity by using the 
binary logistic regression model. Those which showed statistical significant association with 
smear positivity by the binary logistic regression model were put into the multivariable analysis 
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model to check if the association existed after controlling against all the rest of the variables and 
P-value less than 0.05 was considered as statistically significant. 
5.11 Result dissemination 
The final thesis will be submitted to Department of Medical Microbiology, School of biomedical 
and Laboratory sciences, College of Medicine and health sciences and University of Gondar. It 
will then be presented and defended and will be disseminated to North Gondar prison bureau, 
Gondar city administration Health bureau center for disease prevention and control team, plan 
and strategies, and other responsible bodies. The result will be published in international peer 
reviewed journals. Besides, it will be presented in scientific meetings and conferences so as to 
lobby for reformulation of national TB control policy with the necessary attention given to prison 
settings 
5.12 Ethical considerations 
The study was conducted after ethical approval obtained from ethical review committee of the 
School of Biomedical and Laboratory Sciences. Permission to conduct the research was obtained 
from prison authorities through recommendation letter written from the Department of Medical 
Microbiology. An informed consent was obtained from the study participants before 
interviewing and collecting specimen. Positive patients for TB and/or HIV were treated by the 
prison clinics staff following the nation‟s standard for clinical management. 
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6. RESULTS 
6.1. Socio demographic characteristics 
A total of 282 prison inmates suspected for PTB were enrolled in this study. Among these, 
98.2% (277/282) were males, 68.4% (193/282) were married, 50% (141/282) were unable to 
read and write, and 78% (220/282) were urban residents before incarcerated. The mean age of 
the patients was 35 (SD •+11.9) with median age of 30 (range: 16 to 80 years) and 35.1% 
(99/282) were in the age group of 25–34 years (Table 1). 
Table 1: Socio - demographic characters tics of PTB suspected inmates enrolled in the study in 
North Gondar zone prisons from Feb – Apr, 2015. 
Variables Number (%) 
 
Sex  
Male        277 (98.2) 
Female        5 (1.8) 
Age group (in years)        
15-24          63 (22.3)            
25-34        99  (35.1) 
35-44        50 (17.7)        
>45         70  (24.8)        
Residence before incarceration  
Rural       62 (22.0) 
Urban       220 (78.0) 
Educational Status  
No read and write       141 (50.0) 
Elementary        107 (37.9) 
High school and above        34 (12.1) 
Occupation Before imprisonment  
 Civil servant         13  (4.6) 
Farmer          222 ( 78.7) 
Merchant          13 (4.6) 
Student           341(  2.1) 
Marital Status Before incarceration  
Single          77 ( 27.3) 
Married           193 (68.4) 
Divorced            12 (4.3) 
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6.2 Prevalence of pulmonary tuberculosis infection among prison inmates 
The overall prevalence pulmonary tuberculosis infection among prison inmates in North Gondar 
prisons was 5.3 % (15/282) and the point prevalence was 384.6 per 100,000 prison population. 
The prevalence of smear positive prison inmates with MDR-TB was zero (all positive PTB cases 
were RIF sensitive). 
The mean number of prisoners per cell was 233 (±126.5, 35–600). Moreover, 53.5% of the 
prisons had more than 100 inmates per cell which was significantly associated with increased 
risk for tuberculosis infection (AOR=10.32, 95% CI=3.29-8.51). In this study, sharing 
consumables such as food and other materials was significantly associated with tuberculosis 
infection. Prisoners whom were sharing food and other materials were 3.5% times (10/282) 
(AOR= 3.45, 95% CI=1.04-11.49) more at increased risk for tuberculosis infection than those 
inmates that never practiced common food and material usage. Moreover, it was also found that 
prisoners that do not open their cell window regularly had eleven 3.2% (9/282) (AOR= 11.28, 
95% CI=2.25-56.7) times more risk than the corresponding inmates that practiced opening their 
cell window regularly.  
Table 2: Socio-demographic variables of prison inmates in North Gondar Zone Prisons, using 
binary logistic and multivariable logistic regression analysis, N =282 from Feb - Apr, 2015. 
 
Variables 
 
                 Pulmonary tuberculosis suspected inmates 
 
 Positive n 
(%) 
Negative    
n (%) 
 
   Total COR (95%Cl) P-
Value 
 
Adjusted OR 
(95%Cl) 
P-value 
  Age                                 
   15-24 3 (1.1) 60 (21.3)  63 (22.3) 1  1 1 
   25-34  6 (2.1) 93 (33)  99 (35.1) 1.29 (0.31-5.35) 0.72 2.33 (0.52-13.69) 0.662 
   34-44 2 (0.7) 48 (17)  50 (17.7) 0.83 (0.13-5.19) 0.84 1.45 (0.16-13.23) 0.655 
   >45 4 (1.4) 66 (23.4)  70 (24.8) 1.21 (0.26-5.63) 0.80 1.53 (0.24-12.30) 0.890 
  Sex  
  Male 15 (5.3) 262   277 (98.2) 1  1 1 
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(92.9) 
  Female 0 (0)  
 
5 (1.8) 
 
5 (1.8) 0(00) 0.99 1.00 0.99 
  Residence  
  Urban 2 (0.7) 60 (21.3) 62 (22) 1  1 1 
  Rural 13 (4.6) 207 
(73.4) 
220 (78) 1.88 (0.418.5) 0.413 2.81 (0.38-10.07) 0.317 
 Educational status  
   No read 
and write 
7 (2.5) 134 
(47.5) 
141(50) 1  1 1 
Elementary 6 (2.1) 101 
(35.8) 
107(37.9) 1.14 (0.37-3.48) 0.820 1.36 (0.38-4.83) 0.217 
 High 
school and 
above 
2 (0.7) 32 (11.3) 34 (12.1) 1.19 (0.24-6.03) 0.828 4.95 (0.39-62.91) 0.297 
 Occupation before incarcerated  
 Civil  
servant 
0 (0) 13 (4.6) 13 (4.6) 1  1 1 
  Farmer 14 (5) 208 
(73.8) 
222(78.7) 1.08 (00) 0.99  00 0.99 
  Student 
 
1 (0.4) 
 
33 (11.7) 
 
34 (12.1) 
 
4 (89) 
 
0.99 
 
 00 
  
 
Marital status before incarcerated  
 Single 5 (1.8) 72 (25.5) 77 (27.3) 1  1 1 
 Married 10 (3.5) 183 
(64.9) 
193 (68.4) 0.79 (0.26-2.36) 0.67 0.42 (0.09-1.99) 0.277 
 Divorced
  
0(0) 12 (4.3) 12 (4.3) 0 0.99 00 0.99 
Length of stay in prisons (Month)  
  < 2  2 (0.7) 25 (8.9) 27 (9.6) 1  1 1 
 2-6 3 (1.1) 55 (19.5) 58 (20.6) 0.68 (0.11-4.330 0.685 1.54 (0.12-10.30) 0.970 
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* P ⩽ 0.05 (significance level). TB = pulmonary tuberculosis;   OR = odds ratio; CI = Confidence 
interval; COR=Crude odds ratio  
 7-12 2 (0.7) 63 (22.3) 65 (23) 0.40 (0.05-2.97) 0.36 0.79 (0.06-5.65) 0.624 
 >12 8 (2.8) 124 (44) 132 (46.8) 0.81 (0.16-0.53) 0.029 1.02 (0.11-5.26) 0.759 
Frequency of imprisonment  
  Once 14 (5) 258 
(91.5) 
272(96.5) 1  1 1 
 Twice and 
above 
1 (0.4) 9 (3.2) 10 (3.5) 2.05 (0.24-17.31) 0.511 10.52 (0.78-
142.10) 
0.062 
Number of prisoners per cell   
  <50 2 (0.7) 55 (19.5) 57 (20) 1  1 1 
  51-100 1 (0.4)  73 (25.9) 74 (26) 0.38 (0.03-4.26) 0.43 0.19 (0.01-2.90) 0.006 
   
 >100 
 
12 (4.3) 
 
139 
(49.3) 
 
151(53.5) 
 
2.37 (0.52-10.95) 
 
0.048 
 
3.32 (3.29-8.51) 
 
0.002* 
Window opening practice  
  Always   6 (2.1) 108 
(38.3) 
114 (40.4) 1  1 1 
  Some  
times 
 
0 (0) 11 (3.9) 11 (3.9) 00 0.99 00 0.202 
  Never  9 (3.2) 148 
(52.5) 
157 (5 5.7) 1.09 (0.37-3.17) 
  
0.028 11.28 (2.25-56.7) 0.003* 
Sharing of food and materials 
 
  No 5 (1.8)  38 (13.5) 43 (15.2) 1 1 1  
Yes 10 (3.5)  229 
(81.2) 
239 (84.8) 3.01 (0.65-0.97) 0.05 3.45 (1.04-11.49)  
0.044* 
19 
 
6.3. Clinical presentation of PTB among prison inmates 
                                                                    
In this study, the majority 76.6% (216/282) of prison inmates reported that they had cough of 3 
or more week‟s duration. In addition, 80.2% (226/ 282) of the respondents developed the cough 
after imprisonment. Among the eligible study subjects 9.6% (27/282) had history of previous 
treatment for TB and 1.1% (3/282) of them was currently positive for acid-fast bacilli. The 
prevalence of HIV infection among the tuberculosis suspected prisoners was 6% (17/282) and 24 
% (4/17) of the HIV positive prisoners had pulmonary tuberculosis. HIV sero-prevalence was 
significantly associated with pulmonary tuberculosis infection among prisoners (AOR =7.26, 
95% CI=1.10 – 33.30).  
Those prisoners who reported cigarette smoking and had malnutrition (BMI <18.5kg/m2) were 
seven and sixteen times [AOR = 7.16 and 16.26, 95% CI=1.76-29.01 and 4.5-67.9) more likely 
to develop smear positive pulmonary tuberculosis infection than those prisoners who do not 
smoke and with normal nutrition status, respectively. Furthermore, those prisoners who had 
contact with active TB patient in their vicinity were about five times [AOR =5.03, 95% CI = 
1.05-19.30) more likely to develop smear positive pulmonary tuberculosis than those who had no 
history of contact with known tuberculosis patients (Table 3). 
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Table 3: Clinical presentations for TB positivity among   prison inmates in North Gondar zone 
prisons, using binary logistic and multivariable regression analysis, N = 282 from Feb –Jan,2015. 
 
Variables 
 
                 Pulmonary tuberculosis suspected inmates 
 
 Negative 
No (%) 
Positive 
No (%) 
  Total COR 
(95%Cl) 
P-value Adjusted OR 
(95%Cl) 
P-value 
Smoking 
No 232 
(82.3) 
9 (3.2) 241 
(85.5) 
1 1 1 1 
Yes 35 (12.4) 6 (2.1) 41 (14.5) 4.42 
(1.48-
13.17) 
0.008* 7.16 (1.76-29) 0.006* 
Previous contact with TB 
 
No 182 (64.5) 4(1.4) 186 (66)   
1 
 
1 
 
1 
Yes 85 (30.1) 11 (3.9) 96 (34) 5.88 
(1.48-
13.17) 
0.003* 5.03 (1.05-19.6) 0.035* 
 
Time occurrence of Cough 
Before 
imprisonm
ent 
50 (17.7) 6 (2.1) 56 (19.8) 1 1 1 1 
After  
imprisonm
ent 
217 (77) 9 (3.2) 226 
(80.1) 
0.35 
(0.12-
1.02) 
0.05 0.58 (0.15-2.20) 0.328 
 
Duration of Cough (in weeks) 
2 51 (18.1) 2 (0.7) 53 
(18.8) 
1 1 1 1 
3 29 (10.3) 1 (0.4) 30 
(10.6) 
0.88 (0,07-
10.12) 
0.918 0.55 (0.03-8.88) 0.67 
4 63 (22.3) 2 (0.7) 65 (23) 0.81 (0.11-
5.95) 
0.83 0.57 (0.05-6.05) 0.64 
>8 124 (44) 10 (3.5) 134 
(47.5) 
2.05 (0.44-
9.72) 
0.363 1.45 (0.24-8.81) 0.68 
 
Nutritional Status (BMI (kg/m2) 
 
>18.5 238 (84.4) 5 (1.8) 243 
(86.2) 
1 1 1  
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<18.5 29 (10.3) 10 (3.5) 39 
(13.8) 
16.41(5.25
-51.35) 
0.000* 16.26 (3.89-67.96) 0.000* 
  
 
History of previous Treatment 
No 243 (86.2) 12 (4.3) 255 
(90.4) 
1 1 1 1 
Yes 24 (8.5) 3 (1.1) 27 (9.6) 2.53 (0.67-
9.59) 
0.172 0.24 (0.05-1.80) 0.170 
 
HIV Status 
Negative 254 (90.1) 11 (3.9) 265 (94) 1 1 1 
 
1 
 
Positive 13 (4.6) 4 (1.4) 17 (6) 7.12 (1.99-
25.37) 
0.003* 7.26 (1.10-33.31) 0.024* 
        
* P ⩽ 0.05 (significance level). TB = pulmonary tuberculosis; OR = odds ratio; CI = Confidence interval; 
COR=Crude odds ratio  
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7. DISCUSSION 
Prisons are considered as reservoirs for facilitating Mycobacterium tuberculosis (Mtb) 
transmission within their walls, as well as to the community at large. Transmission occurs 
through prison staff, visitors, and released inmates after some time. The estimated prevalence of 
latent TB infection (LTBI) and active TB disease in prison systems are reported to be much 
higher than the average estimates in the general population, irrespective of the economic status 
and the population TB burden of the country [42].  In European prisons, the prevalence of TB 
was estimated to be up to 17 times higher than in the general population [12]. A similar 
epidemiological situations has been described in low and middle income countries including 
Bangladesh, Thailand, and Ethiopia, where TB prevalence has been reported to be almost four, 
eight, and seven times higher, respectively, among prisoners compared to the general population 
[28,26,23]. 
In Ethiopia, a number of epidemiological studies related to TB have been carried out in the last 
decades. However, there are only small numbers of studies that documented the prevalence of 
PTB and MDR-TB among prison inmates in the country in general and in north Gondar 
administrative zone prisons in particular. We believe that the current study can serve as a 
baseline data to fore cast the prevalence of PTB among north Gondar administrative region 
prisons.  
The current study showed a prevalence of 5.3% (15/282) or point prevalence of 384.6 per 
100,000 populations smear positive PTB infection which was 4.6 times higher than the global 
tuberculosis prevalence in the general population [43]. The prevalence of all forms of TB in the 
Amhara Regional State was reported 643 per 100,000 populations while the prevalence of smear 
positive TB infection was 168 per 100,000 populations in the same administrative region. 
Therefore, the prevalence of smear positive PTB infection among north Gondar prisoners was 
2.3 times higher than the prevalence of PTB infection reported among the general population of 
the Amhara administrative region [44]. This indicates an increased risk of transmission of 
tuberculosis which could lead even to an outbreak in any of the north Gondar prisons and the 
general population at large unless immediate measures are taken. However, the prevalence of 
smear-positive PTB infection among the prisoners of north Gondar prisons was lower than the 
prevalence reported in Gamo Goffa zone, southern Ethiopia, which was 19.4%.  Moreover, the 
prevalence of tuberculosis infection in prisons was reported 8-fold higher than the prevalence in 
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the general population in the southern Ethiopia [24] .The prevalence of smear-positive PTB 
infection among north Gondar prisoners was lower than the report from some Ethiopian prisons, 
1913/100,000 in Eastern Ethiopia, and 629/100,000 in Southern Ethiopia [23, 24]. Furthermore, 
there was only one study conducted in a single prison in our setting and the prevalence of smear-
positive PTB infection was reported 1482/100,000 populations which is also higher than the 
prevalence result of the present study [25]. In the present study the prevalence of smear-positive 
PTB was determined among the inmates of the four prisons namely Debark, Dabat, Chilga and 
Gondar towns that may have its own significance to the prevalence difference between the 
current study and the previous one which was conducted only among prisoners of the Gondar 
town. On the other hand, compared to the current result,  lower prevalence of PTB was reported 
from prisons of some Asian, European and African countries, 355/100,000 in Thailand, 
259/100,000 in Taiwan, ,308/100,000 in Uganda and jail of Lahore Malawi, 339/100,000 
[9,26,31,45]. The relatively lower prevalence in these countries could be due to a good TB 
control strategy and low TB incidence in the general population.  
The current study revealed that majority 4.6% (13/282) of the TB positive inmates developed 
cough after they joined the prisons. Longer duration of cough, transfer of prisoners from one 
prison to another before completion of treatment, diagnostic and treatment delay, all could 
contribute for inter-prison and prison-to-population transmission. Moreover, the delay in 
diagnosis and treatment for TB cases may result in an MDR-TB epidemic unless appropriate 
attention is given to the prison population. 
In the present study, none of the smear-positive prisoners showed any type of drug resistance 
against rifampicin which was determined by the Gene Xpert technology. Drug resistance against 
the anti-TB drug rifampicin was previously used as a surrogate maker of drug resistance and 
MDR-TB against anti-TB drugs. Different reports showed a higher rate of MDR-TB infection 
among prisoners in different parts of the world and some African prisons [19, 24, 28, 29]. For 
example, the rates of resistance were significantly higher in prisoners, with rate ratios (RR) of 
1.9 for MDR-TB [27].  
Even though there wasn‟t any significant association between the duration of cough and TB 
positivity in this study, it could still show an extended time before patients get diagnosed and 
treated rendering the smear positive prisoners to transmit the infection to many others. This 
24 
 
could be intensified by the nature of the cells shared by the inmates. The number of inmates per 
cell more than 100 was significantly associated (P=0.001) with PTB positivity. Indicating cells in 
the study area were poorly ventilated and overcrowded. Inmates who share their food and 
materials with their colic‟s were significantly associated with PTB positivity (P=0.044). This 
could enhance high TB transmission with in prison inmates and can further has a chance to 
transmit to the general community because they interact directly with their families or other 
relatives who come to visit them. 
The result of this study showed that prisoners who reported cigarette smoking were seven times 
more likely to develop smear positive pulmonary tuberculosis infection than those prisoners who 
do not smoke. Several studies have linked smoking with tuberculosis [46, 47] used binomial 
regression to propose that heavy smoking was associated with pulmonary tuberculosis. The 
alveolar macrophage is probably the first cell to ingest a tubercle bacillus following infection. 
These cells suppress the local immune response in order to preserve lung architecture and both 
smoking and tuberculosis induces apoptosis of these cells [48, 49].  
Malnutrition prisoners were found sixteen times more likely to develop tuberculosis compared 
with normal prisoners. The association between tuberculosis infection and malnutrition has been 
recognized for a long time. Malnutrition may predispose to TB, and in turn TB often causes 
malnutrition [50, 51] .In a rat model as a consequence of malnutrition, there were lower numbers 
of alveolar macrophages (AMs) in the broncho alveolar lavage fluid and toxic radical such as 
NO releases by AMs were impaired. Moreover, monocytes obtained from malnourished adult 
patients suffering from fibrocaseous TB showed inadequate stimulation even with recombinant 
gamma interferon. These results suggest macrophage dysfunction to produce NO2- in 
malnourished patients suffering from TB [52].  
The study results show that having PTB was significantly associated with history of active TB 
patient contact (P=0.035). Thirty percent of inmates having history of previous contact with 
active TB patients showed clinical signs and symptoms for PTB and among these inmates 3.9% 
were positive for PTB. This shows that tuberculosis causing bacteria is circulating in the prisons 
that make the risk of acquiring TB in prisons very high.  
In the current study, 6% (17/282) of the prisoners were found reactive for HIV antibody test and 
1.4% (4/282) of them had PTB co-infection. The prevalence of HIV infection in the TB infected 
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inmates was calculated 24%. The prevalence of TB/HIVco- infection in the current study was 
higher than reports from Spanish and Tanzanian prisoners that showed 17.9% and 22% PTB/HIV 
co-infection, respectively [37,53].  While it was lower than the study conducted in North west 
Ethiopia and Malawian prisoners who had PTB/HIV co-infection in up to 34.6 and 73% of the 
cases, respectively [25,9]. A core challenge to TB control in prison systems is dealing with the 
dual epidemics of HIV and TB, as well as other co-infections such as with hepatitis B or C virus. 
Given the impact that HIV has on TB cases and vice versa, coordination between TB and HIV 
programmes is vital [54].  However, this may be limited due to poor surveillance of HIV among 
prisoners with TB, challenges in the diagnosis of TB among people living with HIV and lack of 
joint planning and mobilization for TB/HIV co-infection, and inadequate human resources 
capacity for managing TB/HIV [19, 54]. In addition, a coordinated system, supported by the 
ministries of health, welfare, and justice or interior, should implement a holistic approach to 
patients in correctional facilities. 
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8. CONCLUSION 
The point prevalence of smear-positive pulmonary tuberculosis infection among north Gondar 
prisoners was 384.6 /100,000. The prevalence of smear positive pulmonary tuberculosis infection 
among North Gondar zone prisoners was found to be 2 times higher than the general population. 
High number of inmates per cell, smoking, malnutrition, sharing of food and materials, and 
previous history of contact with active TB cases were found significant risk factors for to acquire 
tuberculosis in prisons. The majority of the TB positive inmates developed cough after they 
joined the prisons which might indicate that they acquired TB within the prison. Six present of 
the prisoners were positive for HIV and the serum of half of the smear-positive TB cases were 
reactive for HIV antibody. 
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9. RECOMMENDATION 
Failure to control tuberculosis in prisons has the potential to disseminate tuberculosis to the 
general population. Therefore, establishing active and regular tuberculosis screening program 
requires urgent implementation. Reducing the burden of prison inmates within a particular cell, 
restricting access to smoking and establishing ventilation system can possibly minimize the 
transmission of tuberculosis among prisoners. Screening prisoners for HIV infection prior 
imprisonment may clarify the risk of acquiring HIV within the prison particularly for prisoners 
incarcerated for long period of time. Furthermore, preventive activities, including wider health 
education (e.g. needle exchange or cleansing programmes, or safe sex), prevention of 
malnutrition among prisoners possibly contribute to reduce the burden of tuberculosis infection 
in prisons.  
 Further large scale research should be conducted on the prevalence of PTB and MDR-TB 
infection and potential risk factors in prisons using advanced diagnostic tools such as culture and 
Gene Xpert. In addition, evidence of the circulating strains, genotyping and transmission 
dynamics inside the prison setting is also warranted. 
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 ANNEXES 
ANNEX I: Questionnaire for the prevalence pulmonary tuberculosis in prison settings   
A. Socio demographic information  
1. Unique Inmate number/ code no.________ 
2. Age______ 
3. Sex_____ 
4. Residence before incarceration : Urban    Rural  
5. Educational status   Illiterate    Read and write    
Elementary  High school   
College and above       
6. Occupation before imprisonment: civil servant (gov‟t)    Farmer    
  Self employed              Merchant  
  Student                          House wife    
7. Marital status before incarceration: Single    married    divorced     widowed      
B. Clinical risk factors 
8. Smoking              Yes     No   
9. Previous contact with individual with active TB:     Yes     No   
10. Length of stay in the prisons (in months):        <2     2-6    7-12   >12   
11. Do you detain in the prison? Yes  No  
12. If yes, for how many is frequency of imprisonment:   once     twice or more                      
13. Number of prisoners per cell:   <50     51-100      >100   
14. Duration of Cough (in weeks):   > 2    3    4   >8      
 15. Sharing food and drink materials:   Yes     No   
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 16. Window opening practice of inmates    never:       sometimes      always                         
 17. Time of occurrence of the cough:    Before imprisonment     
                                                                After imprisonment  
 18. Nutritional status:   Under nutrition (BMI < 18.5kg/m2)  
                                     Normal nutrition (BMI >18.5kg/m2)   
 19. History of previous treatment:   Yes     No   
 20. HIV status of the inmates:      Positive       Negative  
ጎንዯር ዩኒቨርስቲ 
የ ህክምናና ጤና ሣይንስ ኮላጅ 
የባዮሜድካሌ እና ሊቦራቶሪ ሣይንስ ትምህርት ቤት 
 
በሰሜን ጎንዯር ዞን የሚገኙ ማረሚያ ቤቶች  የቲቢ በሽታ ይኖርባቸዋሌ ተብል ሇተገመቱ ታራሚዎች ሇበሽታው ሉያጋሌጡ 
ስሇሚችለ ተያያዥ ጉዳዮችንና ማሀበራዊ ኢኮኖሚየዊ ጉዳዮችን ሇማወቅ የተዘጋጀ መጠይቅ           
ሀ. ማሀበራዊ  ጉዳዮች 
  1.የታራሚዉ ሚስጥራዊ ቁጥር………………….      
  2.እድሜ----------------- 
  3.ፆታ፡   ወንድ፡     ሴት    
  4.መኖርያ ከተማ፡   ገጠር   
  5.የትምህርት ሁኔታ፡ ያሌተማረ        የሚያነብና የሚጽፍ   
                       1ኛ ዯረጃ ት/ቤት     2ኛዯረጃ ት/ቤት    ኮላጅና ከዛ በሌይ  
  6.የሥራ ዓይነት፡ የመንግስት      ተማሪ        ገበሬ   
                     ነጋዴ          የቀን ሰራተኛ     የቤት ሰራተኛ   
  7.የጋብቻ ሁኔታ፡ ያሊገባ         ያገባ         የፈታ      የፈታ    
 ሇ. የጤናና ላልች ተያያዥ ጉዳዮች 
  8. ሲጋራ ያጨሳለ? አዎ  አይዯሇም  
 9. ከዚሀ በፊት ቲቢ ከያዘው ሰው ጋር ግኑኝነት ነበርዎ? አዎ      አይዯሇም  
10.በ ማረ ምያ ቤት  ለ ስ ን ት  ግ ዜ  ቆ ዩ (በወር)? <2    2-6  7-12  >12  
 11. ከ ዚህ  በ ፊ ት  በ ማረ ምያ ቤት  ገ ብተው ያ ውቃሉ? አ ዎ አ ላ ውቅ ም  
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 12. መሌስዎ አዎ ከሆነ ሇስንት ግዜ?  አንድ ግዜ   ሁሇት ግዜ እና ከዛ በሊይ  
 13. በአንድ የማረምያቤትክፍሌ የሚኖሩ የታራሚዎዎች ብዛት፡ <50   51-100    >101  
 14. ሳለ ከጀመረህ ስንት ግዜ ይሆነዋሌ(በሳምንት)? > 2    3    4   >8    
15.  አብሮ መብሊትና መጠጣትባህሌ ፡ አዎ  አይዯሇም  
16.መስኮት የመክፈት ባህሌ ፡ አንከፍትም   አሌፎ አሌፎ   ሁሌግዜ   
17.ሳለ የከመረቦዎት መቼ ነው? ማረምያቤት ከመምጣቴ በፊት         ማረምያቤት ከመጣሁ ብኋሊ   
18.የጠየና ሁኔታ በክንዯት( ኪ.ም/ሜ2)፡  የሜና እክሌ አሇበት(BMI < 18.5 ኪ.ም/ሜ2)   
                                                     ሜናማ (BMI >ኪ.ም/ሜ2)    
19.ከዚህ በፊት የቲቢ መድሀኒት ወስዯው ያውቃለ? አ ዎ አ ላ ውቅ ም  
 20.የ ኤች አ ይቪ ሁኔታ፡  ፖዘቲቭ     ነጋቲቭ   
Annex II.  Laboratory procedure LED florescent microscope  
 
A. Smear preparation: 
Smears should be prepared in manageable batches, suggestively not more than 12 smears per 
batch. Make sure all smear-samples are labeled with a name or number. Prepare smears from 
processed specimens such as liquid suspensions obtained from ground or homogenized tissue, 
sputum, or decontaminated inoculate, in a Bio safety cabinet type I.  
1. Label new, clean, unscratched microscope slide at one end with the relevant sample 
name/number. Avoid touching the surface of the slide. 
2. Thoroughly mix the specimen with a pipette (1ml) and place about one drop (or 2 – 3 
loopfuls) on the slide. 
3. Using stick applicator spread the smear over a surface of about 2cm x 3cm. 
4. Allow the smear to air dry completely in the BSC I. Do not use heat for drying! 
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5. Heat-fix the slide either by passing it through a flame three to four times with the smear side 
up. Alternatively, allow the slide to fix on an electric slide warmer at 65 - 75ºC for 2-3 hours or 
overnight. Do not overheat or expose smears to UV light (6). Let the slide cool before staining. 
B. Staining procedures for LED fluorescence microscope 
1. Label a new clean, unscratched slide at one end with the laboratory number using diamond 
tipped stylus 
2. Use muco-purulent portion for smear preparation. Transfer an appropriate portion of the 
specimen to the slide by using a broom-stick or nichrome wire loop of 5mm dm (27 SWG). 
3. Smear the specimen over an area of approximately 2 by 3 cm. Make it thin enough to be able 
to read through it. Use a fresh slide for each specimen 
4. Allow smears to air-dry for 15 minutes. Do not use heat for drying 
5. Fix the smear to the slide by passing it over the flame 3 to 5 times for 3 to 4seconds each. 
6. After making smear, burn and dispose the broom-stick or flame wire loop thoroughly using 
side burner prior to re-use. 
7. Place the slides on a staining rack, with the smeared side facing up, the slides not touching 
each other 
8. Flood the slides with freshly filtered auramine-phenol. Let stand for 7-10 
Minutes 
9. Wash well with running water, taking care to control the flow of water so as to prevent 
washing away the smear 
10. Decolorize by covering completely with acid-alcohol for 2 minutes, twice 
11. Wash well with running water, as before to wash away the acid alcohol 
12. Counter stain with 0.1% potassium permanganate for 30 seconds 
13. Wash as before with water and slope the slides to air dry 
14. Switch on the mercury vapor lamp. The bulb takes approximately 10 minutes to reach full 
intensity. Using the low power objective (magnification 100-150x) first examine a known 
positive slide to ensure that the microscope is correctly set up. 
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15. With auramine staining, the bacilli appear as slender bright yellow fluorescent rods, standing 
out clearly against a dark background. 
 
Auramine O fluorescent staining grading 
(using 20 or 25x objective and10x eye piece) 
Reporting /Grading 
>100 AFB/field after examination of 20 fields 
11-100 AFB/field after examination of 50 fields 
1-10 AFB/ field after examination of 100 fields 
1-3 AFB/100 fields  doubtful positive /repeat 
No AFB per 100 fields  Negative 
 
 ANNEX III .Laboratory procedure for Xpert MTB/RIF 
Sample Procedure 
1. Mix “Sample reagent buffer SRB ” with the sample (Add 2:1 sample reagent buffer to 
sample ratio)  
 
A. Shake then stand 10 minutes  
B. Shake then stand further 5 minutes.  
 
Note: After 15 min incubation, if the mixture remains viscous, shake the sample 
again and leave it for additional 5 min until it gets liquefied.  
2. After 15 minutes incubation at room temperature: 
A. Remove Xpert cartridge from its wrapper. Take care not to touch the back of the 
cartridge  
B. Label the side of the Xpert cartridge with the sample ID. Do not write or place 
sticker over cartridge barcode. 
C. Open the lid of the cartridge. 
D. Open the lid of the collection container containing the mixed sputum specimen. 
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E. Open a sealed sterile pipette (supplied in kit) without touching the tip. Use the 
pipette to aspirate >2ml of the specimen (just above 2ml mark on pipette) Note: 
Do not add less than 2ml of mixed specimen to the cartridge.  
F. Slowly transfer/dispense  2ml SRB and sample mixture into the open port of the 
Xpert MTB/RIF cartridge (loading  in to the Xpert MTB/RIF cartridge) 
G. Close the cartridge lid firmly. 
H. Dispose of the specimen collection container, pipette and leftover SR buffer into a 
suitable medical waste bin. 
I. Take the Xpert cartridge to the bench with the GeneXpert instrument.  
J. Show the proper disposal of leftover SR buffer, used transfer pipettes, and etc 
K. Remove your gloves and hand wash and change a new glove before you are going 
to load to GeneXpert instrument  
L. Insert the cartridge and start the test. Test should be launched within 30 minutes. 
3. Running the test 
4. Interpreting test  results 
o After completion of the run, click on the „View Results’ icon on the system toolbar. 
o Click on „View Test‟ at bottom of the result screen toolbar. 
o Select the patient test by clicking on the patient ID field. This will highlight the test.  
o  Click „OK‟ and the result screen will be displayed as one of the following: 
 MTB DETECTED – positive (with/out RIF resistance)  
 MTB NOT DETECTED - negative 
 INVALID – repeat test 
 ERROR – repeat test 
 NO RESULT – repeat test 
5. Reporting 
 MTB detected  
 MTB not detected 
 RIF Resistance detected 
 RIF resistance not detected 
 RIF resistance indeterminate 
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ANNEX IV:  Consent form  
Dear Madam/sir  
My name is    Teklay Gebrecherkos and I am from the School of Biomedical and Laboratory 
Sciences, University of Gondar. I am gonging undertake a research entitled “Prevalence and 
MDR PTB in prison settings of North Gondar zone, Northwest Ethiopia”. I am going to 
assess the prevalence of smear positive TB and multi drug resistance due to different associated 
factors in three prisons of north Gondar. So this study will help us to determine the magnitude of 
the problem that will be farther contribute to create awareness and plan new strategy for policy 
makers and responsible bodies. The information from this study will not be used for other 
purposes by any of the institutions and individuals without your agreement and the information 
will be completely confidential. If you do have any questions or problems at any time, you can 
contact me by mobile: 0922795314 or by Email: tgchirkos@yahoo.com  
     Your sincerely 
    Teklay Gebrecherkos 
On behalf of ------------Prison inmate, I the undersigned have understood the objective of the 
study in titled with “Prevalence pulmonary tuberculosis in prison settings of North Gondar 
zone, Northwest Ethiopia” and I agreed what is explained by the investigator. I also allowed to 
him to give all the required information and enough amount of Sputum samples for laboratory 
analysis and other information.  
 
       Name……………………………………….Signature…………….. ………Date …………. 
eUU’ƒ 
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“Prevalence and MDR PTB in prison settings of North Gondar zone, Northwest Ethiopia” 
uT>M `°e U`U` eKTŸN?É KT>ÖÃn‹G< SÖÃp“ ¾›¡}“S<“ eKUðMÓ ƒww` •}Å`Ñ<M˜ ²”É uƒIƒ“ ›¾Ö¾pG< 
¾U¨eÅ¨<” “S<“ u`°c< Ÿ}Ökc¨< ›LT ¨<ß ¾TÃ¨<M SJ’<”  
›Á[ÒÑØG< uT˜—¨<U Ñ>²? ØÁo ŸK­ƒ ueM¡ lØ` 0922795314 ¨ÃU u›=T@M tgchirkos@yahoo.com SÖ¾p 
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